| This week's sponsor is ExL Events. | | | |
| How does a company win or lose in its public debut? Did it raise a lot of money? Did investors pay a higher price than expected? Of course, it can be more complicated than that—closing at the top of the range and raking in millions is never the whole story. While some are still just starting out, the companies we can judge are those that have translated their promises into successful products—or those that have failed miserably. Read on for our top biotech IPO winners and losers, from 2012 to today, plus the top stories from this week. | |
|
Featured Story | | | Tuesday, September 10, 2019 Merck’s Keytruda-chemo combo has a history of silencing its critics when it comes to its effectiveness in previously untreated NSCLC patients. And it may have just done it again. A pooled analysis from three trials showed that the combo majorly cut patients’ risk of death, even among those whose tumors tested negative for PD-L1. |
|
|---|
|
Top Stories Of The Week Tuesday, September 10, 2019 Investors may gauge a biotech IPO by how much it raised and how much the stock appreciates, but the true measure of success is simple: What did it achieve with the cash? Here, we take a look at biotechs that went public and got a drug to market, as well as those that fizzled after their IPO. Friday, September 6, 2019 Sumitomo Dainippon is set to pay $3 billion upfront to buy Roivant’s stake in five of its Vant startups. The deal could provide Dainippon with a series of new product launches to offset the loss of patent protection on bipolar depression drug Latuda. Wednesday, September 11, 2019 Bayer’s restructuring ax has hit the top—the company’s board of management. Two C-level execs, including one who's under blame for an FDA warning letter that restrains some of Bayer's drug supplies, will leave first thing next year as the company tries to cut costs. Monday, September 9, 2019 Amgen unveiled data for the highest dose of its KRAS inhibitor, showing it kept cancer at bay in 100% of lung cancer patients and shrank tumors in more than half of them. Though the data were impressive, Amgen's stock dipped in premarket trading. Friday, September 6, 2019 Stryker is snapping up CT scanner manufacturer Mobius Imaging—along with the latter’s sister company focused on spine surgery robotics—in a $500 million deal that bolsters its spine division’s capabilities in image-guided procedures. Monday, September 9, 2019 Novartis, under fire for manipulating data for its gene therapy Zolgensma and for delays in alerting the FDA, has come up with a late fix. It will inform the agency of any "credible allegation" of data integrity within five business days, CEO Vas Narasimhan told investors Monday. Friday, September 6, 2019 Takeda’s been looking for a buyer for Natpara to provide some debt relief, but it has just run into some complicating circumstances. It is having to recall the drug from the market, a move it says may be very challenging for patients. Wednesday, September 11, 2019 Several cancer drug candidates in clinical trials are designed to kill tumor cells by attacking certain targets, but they actually work in other ways, a study by Cold Spring Harbor Laboratory has found. Wednesday, September 11, 2019 Pfizer’s been making a few changes to its cancer executive team over the past few years, and today it’s making another as Vassiliki Papadimitrakopoulou, M.D., joins as the new clinical development leader at its oncology unit. Friday, September 6, 2019 Following Eli Lilly and Sanofi, Novo Nordisk has become the last of the Big Three insulin makers to have come up with a plan to lower its insulin prices amid mounting criticism over their high costs in the U.S. | This week's sponsor is FiercePharmaMarketing. | | | |
Resources Sponsored by: Patheon, by Thermo Fisher Scientific Avoid potential risks to the patient as well as costly interruptions during development. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: AlphaSense AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy. Sponsored by: Elemental Machines Your lab is talking to you, are you listening? Sponsored by: Frenova Want to be sure your renal research protocol design is fit for the real world? Sponsored by: Recro Gainesville Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities? Sponsored by: Baxter BioPharma Solutions Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 